Escape from immunotherapy: possible mechanisms that influence tumor regression/progression

Ahmad, Murrium; Rees, Robert C.; Ali, Selman A.

doi:10.1007/s00262-004-0540-x

Cited by 167 publications

(117 citation statements)

References 117 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…However, thus far, a safe, efficient, and clinically applicable method has yet to be developed. The principal difficulty inherent to cancer immunotherapy involves the immune escape mechanism, or poor immunogenicity, of tumors (Ahmad et al, 2004;Seliger, 2005). More specifically, the expression of class I-and II-major histocompatibility complex MHC proteins is frequently suppressed in tumors (Garcia-Lora et al, 2003;Ogino et al, 2003;Vitale et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor immunostimulatory effect of heat-killed tumor cells

Yoon

Kim

et al. 2008

Exp Mol Med

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Anti-tumor immunostimulatory effect of heat-killed tumor cells

Yoon

Kim

et al. 2008

Exp Mol Med

View full text Add to dashboard Cite

“…The escape of cancerous cells may be due to a number of factors such as weak immunogenicity, lack of proper communication between immune cells and the tumor cells, low to absent expression of major histocompatibility complex molecules, immunologic tolerance, higher regulatory (suppressor) T cells, absence of lymphocytes targeting the tumor and suppressive activities (such as deposition of IDO: Indoleamine 2, 3-dioxygenase) produced by the tumor itself. [39][40][41][42] Along with such immunoregulatory factors, there are various critical epidemiological parameters that include patient education, customized diets, nutritional supplements, psychotherapies, detoxification therapies, environmental controls and pharmaceuticals. 9,11 It is suggested that an appropriate utilization of such factors can help to cure about half of all individuals who develop cancer.…”

Section: Development Of Tumor Vaccinementioning

confidence: 99%

Prostate cancer: genes, environment, immunity and the use of immunotherapy

Karan

Thrasher

Lubaroff

2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate cancer remains the most prevalent noncutaneous cancer, leading to almost 30 000 deaths every year in men in the United States. A large body of knowledge emphasizes a strong influence of epidemiological factors such as lifestyle, environment and diet, on the development of prostate cancer. Although risk reduction of prostate cancer has been somewhat successful, effective prevention is still lacking. Immunotherapeutic approaches, although moderately complicated, remain promising in an effort to control the progression and development of the disease. Taken together, the parameters of epidemiological studies and immunotherapeutic regimens might eventually be the most effective and preventive approach for prostate cancer. This review highlights some of the events associated with the development and prevention of prostate cancer.

show abstract

“…1 T2 cells (7.5 3 10 3 per well) were loaded with the analog peptide MelanA/MART-1 [26][27][28][29][30][31][32][33][34][35] or Tyrosinase 368-376 (30 lM) as a control. After 20 hr, cytokine release of individual CD8…”

Section: A2mentioning

confidence: 99%

Induction of strong and persistent MelanA/MART‐1‐specific immune responses by adjuvant dendritic cell‐based vaccination of stage II melanoma patients

Tuettenberg

Becker

Hüter

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

A significant percentage of stage II melanoma patients (tumor thickness >1 mm) remain at risk of tumor recurrence after primary tumor excision. In this study, we used tumor antigen-pulsed dendritic cells as an adjuvant for immunization of these ''highrisk'' melanoma patients after resection of the primary tumor. A total of 13 patients were included and vaccinated 6 times every 14 days with autologous dendritic cells pulsed with a MelanA/ MART-1 peptide in combination with a recall antigen. Antigenspecific immune responses were monitored before, during and up to 1 year after the last vaccination. The majority of patients exhibited increased recall antigen-specific CD4 1 T cell responses upon vaccination. MelanA/MART-1-specific CD81 T cells were expanded in 9/13 patients resulting in increased frequencies of memory cells in these patients. CD81 T cells acquired the capacity to secrete IFN-c, to proliferate in culture in response to the tumor antigen used for vaccination and postvaccine samples contained MelanA/MART-1-specific T cells that recognized also the natural MelanA/MART-1-antigen expressed by tumor cells. Moreover, vaccination induced a long-lived tumor antigen-specific DTHreactivity in the majority of the patients, detectable even 12 months after the last immunization. These data demonstrate for the first time that vaccination with tumor antigen-pulsed dendritic cells in a clinically adjuvant setting induces strong and persistent antigen-specific T-cell responses in tumor-free stage II melanoma patients, suggesting that tumor protective T cell immunity can be achieved. ' 2005 Wiley-Liss, Inc.

show abstract

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression

Cited by 167 publications

References 117 publications

Anti-tumor immunostimulatory effect of heat-killed tumor cells

Anti-tumor immunostimulatory effect of heat-killed tumor cells

Prostate cancer: genes, environment, immunity and the use of immunotherapy

Induction of strong and persistent MelanA/MART‐1‐specific immune responses by adjuvant dendritic cell‐based vaccination of stage II melanoma patients

Contact Info

Product

Resources

About